Search the Newsreel

Stronger Revenue and Narrower Loss Might Change The Case For Investing In CRISPR Therapeutics (CRSP)

CRISPR Therapeutics (CRSP) CFO Prasad Raju makes bona fide gift of 750 shares

CRISPR Therapeutics AG's Chief Financial Officer, Prasad Raju, reported a bona fide gift of 750 Common Shares on August 7, 2026. This transaction is classified as a disposition, and following the gift, Raju directly holds 14,815 Common Shares. The Form 4 filing indicates the …

CRISPR Therapeutics AG (CRSP) Stock Forecasts

This article provides an analyst report from Morningstar on CRISPR Therapeutics AG (CRSP), noting that its gene-editing therapy Casgevy is gaining traction despite initial commercial hurdles. The report highlights the company's focus on CRISPR/Cas9-based therapeutics. It also includes various market data and related analyst …

CRISPR Therapeutics AG $CRSP Stock Position Raised by Quantinno Capital Management LP

Quantinno Capital Management LP significantly increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 613.5% in the first quarter, now owning 47,989 shares valued at $2.28 million. Institutional investors hold 69.2% of the company, and analysts maintain a "Moderate Buy" rating with an average …

CRISPR Therapeutics (CRSP) Earnings Drew Fresh Interest, Is The Stock Below Fair Value?

CRISPR Therapeutics (CRSP) reported improved Q2 2026 results with higher revenue and a reduced net loss, leading to a short-term stock rebound. Despite mixed long-term performance, a discounted cash flow (DCF) model suggests the stock is significantly undervalued at $53.52 compared to a fair …

CRISPR Therapeutics (NASDAQ:CRSP) Rating Increased to Hold at Wall Street Zen

Wall Street Zen has upgraded CRISPR Therapeutics (CRSP) from a "Sell" to a "Hold" rating, while the broader analyst consensus remains a "Moderate Buy" with an average target price of $68.06. Despite a recent 3.6% increase in share price, the company reported a quarterly …

Goldman Sachs Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)

Goldman Sachs has reiterated a Hold rating for Crispr Therapeutics AG (CRSP) with a price target of $55.00. This follows similar Hold ratings from other analysts like Wells Fargo, though H.C. Wainwright maintained a Buy rating. The company recently reported quarterly revenue of $10.18 …

Dimensional Fund Advisors LP Sells 412,889 Shares of CRISPR Therapeutics AG $CRSP

Dimensional Fund Advisors LP significantly reduced its stake in CRISPR Therapeutics AG by 45.5% in the first quarter, selling 412,889 shares. Following the sale, the firm now owns 494,218 shares valued at $23.49 million. The article also covers recent analyst ratings, insider trading activity, …

Why CRISPR Therapeutics (CRSP) Is Up 11.6% After CASGEVY Expansion And Pipeline Updates - And What's Next

CRISPR Therapeutics (CRSP) saw its stock rise by 11.6% following its second-quarter 2026 results, which included an increase in revenue to US$10.18 million, a narrowed net loss, and the expansion of CASGEVY's FDA approval to younger children. The company also announced new in vivo …

CRISPR Therapeutics AG (NASDAQ:CRSP) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

CRISPR Therapeutics AG (NASDAQ:CRSP) reported strong second-quarter revenues of US$10m, significantly beating estimates, and a smaller-than-expected statutory loss. Following these results, analysts have substantially increased revenue forecasts for 2026 to US$54.4m and reduced expected losses, anticipating significant growth. Despite these upgrades, the consensus price …

Piper Sandler Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Crispr Therapeutics AG (CRSP) with a price target of $110.00. This follows similar Buy ratings from William Blair, though Morgan Stanley maintained a Hold. The company recently reported Q2 revenue of $10.18 million and …

Crispr Earnings: Casgevy Gains Traction as Commercial Hurdles Begin to Ease

CRISPR Therapeutics AG Stock 12‑Month Price Target Raised to $84.39, Implies 70% Upside

The average 12-month price target for CRISPR Therapeutics AG (CRSP) stock has been raised to $84.39 from $83.94, based on estimates from 18 analysts. This updated target implies a potential upside of approximately 70% from its Aug. 3 closing price. The consensus rating among …

Crispr Therapeutics Posts "Quiet" Quarter as Casgevy Advances, SiRNA Data Readouts Near, RBC Says

Crispr Therapeutics (CRSP) reported a relatively quiet Q2, with Casgevy continuing to gain commercia PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …

CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates

CRISPR Therapeutics (CRSP) reported a narrower-than-expected loss of 94 cents per share for Q2 2026, surpassing the Zacks Consensus Estimate of a $1.10 loss. The company's total revenues also exceeded expectations, reaching $10.2 million against an estimate of $7 million, driven by strong collaboration …

Crispr Therapeut (CRSP) Stock News & Updates

This page provides news and updates for Crispr Therapeutics (CRSP), a company focused on gene-based medicines. Recent updates include a Q2 2026 financial report showing $76 million in CASGEVY revenue and advancements in multiple clinical programs. The company also announced participation in several investor …

Crispr Therapeutics earnings beat by $0.26, revenue topped estimates

Crispr Therapeutics reported a second-quarter EPS of $-0.94, surpassing analyst estimates by $0.26, and revenue of $10.18M, which also topped the consensus estimate. Despite the strong earnings beat, the company's stock price has seen declines over the last three and twelve months. InvestingPro assesses …

Crispr Therapeutics AG (CRSP) rebounds 3.1% before Aug. 3 earnings, but trend stays inactive

The gene-editing biotech reports with medium-term performance still under pressure and volume running below its 13-week average.

CRISPR Therapeutics (NASDAQ:CRSP) Announces Quarterly Earnings Results, Beats Estimates By $0.26 EPS

CRISPR Therapeutics (NASDAQ:CRSP) announced its quarterly earnings, reporting an adjusted loss of $0.94 per share, significantly beating analyst estimates of a $1.20 loss. The company also surpassed revenue expectations, bringing in $10.18 million against an estimated $7.45 million. Following these results, CRSP shares rose …

Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q2 Revenue $10.2M, vs. FactSet Est of $7.4M

CRISPR Therapeutics AG (CRSP) reported Q2 revenue of $10.2 million, significantly surpassing the FactSet estimate of $7.4 million. This earnings flash highlights the company's financial performance for the second quarter and six months ended June 30, 2026. The article also mentions the company's recent …

CRISPR Therapeutics reports $91.2 million second quarter net loss

CRISPR Therapeutics (CRSP) reported a net loss of $91.2 million for the second quarter of 2026, a significant improvement from the $208.5 million loss in the same period last year, while total revenue increased to $10.2 million. The company's gene-editing therapy, CASGEVY, generated $76 …

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

CRISPR Therapeutics reported strong execution across its portfolio in Q2 2026, highlighted by continued momentum for CASGEVY with FDA approval for children as young as 2 and expansion of its in vivo pipeline. The company initiated Phase 1 trials for CTX340 for refractory hypertension …

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss of $0.94 per Share

CRISPR Therapeutics AG (CRSP) reported a Q2 loss of $0.94 per share on revenue of $10.18 million, missing analyst revenue estimates but exceeding them on earnings per share. The company saw significant growth in revenue from its lead drug, CASGEVY, with a 151% year-over-year …

CRISPR Therapeutics (CRSP) Expected to Release Earnings on Monday

CRISPR Therapeutics (CRSP) is anticipated to release its Q2 2026 earnings on Monday, August 10th, with analysts forecasting a loss of $1.20 per share and revenue of $7.45 million. The company's shares are currently trading near their 52-week low, and it remains unprofitable, though …

CRISPR Therapeutics (CRSP) Rebounded In Its Latest Session, Is It Still Well Below Fair Value?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. CRISPR Therapeutics Stock Reaction To Recent Trading Session CRISPR Therapeutics (NasdaqGM:CRSP) recently finished a trading session with a positive price move that outpaced the S&P …

CRSP Stock Price and Chart — NASDAQ:CRSP

This page provides a comprehensive overview of CRISPR Therapeutics AG (CRSP) stock, including its current price, historical performance, key financial statistics, and company details. It also features a collection of recent news and trading ideas from analysts and community members regarding CRSP's stock movement, …

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (CRSP) and GlaxoSmithKline (GB:GSK)

This article discusses mixed analyst opinions on two healthcare stocks: Crispr Therapeutics AG (CRSP) and GlaxoSmithKline (GB:GSK). Crispr Therapeutics received a "Moderate Buy" consensus with an attractive price target upside, while GlaxoSmithKline holds a "Hold" consensus with a modest upside. The report highlights specific …

CRISPR Therapeutics AG (CRSP) Financial Health: Profitability & Balance Sheet Analysis

CRISPR Therapeutics AG (CRSP) has a weak financial status with a current financial score of 6.45, ranking 242 out of 384 in its industry. Despite a 68.55% year-over-year revenue increase to $1.46M and a 9.61% net profit increase, its operating efficiency is low. The …

CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider

CRISPR Therapeutics AG (CRSP) saw a 1.68% increase in its stock price, outperforming the S&P 500's daily gain, despite a 14.35% decrease over the last month. Analysts anticipate positive year-over-year growth in upcoming earnings, with expected earnings of -$1.1 per share and revenue of …

How Crispr Therapeutics Ag (CRSP) Affects Rotational Strategy Timing

This article analyzes Crispr Therapeutics Ag (NASDAQ: CRSP) using AI models to provide trading strategies. It highlights weak sentiment across all horizons, suggesting a short bias, and details position, momentum breakout, and risk hedging strategies with specific entry, target, and stop-loss levels. The analysis …

Price to earnings forward of CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh – SET:CRSP03

This article focuses on the "Price to earnings forward" metric for CRISPR Therapeutics AG Shs Thailand Depositary Receipts, traded on the Stock Exchange of Thailand under the symbol CRSP03. It's a financial data point from TradingView, indicating a specific period, value, and change for …

3 Mid-Cap Growth Stocks With Monstrous Long-Term Upside

Investing in stocks with modest valuations can set investors up for some significant returns in the long run. While there is more risk involved in putting money into smaller, less-established businesses, the upside can also be considerable, potentially resulting in massive gains. Three mid-cap …

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

CRISPR Therapeutics AG (CRSP) has garnered investor attention, appearing on Zacks.com's list of most searched stocks. Despite a recent share decline, the article highlights the importance of earnings estimate revisions, revenue growth potential, and valuation in assessing the stock's future. CRISPR Therapeutics currently holds …